Moreover, some subtypes of DLBCL carry genetic mutations that activate BCR signaling, including mutation in CD79B and CARD11, where the latter mutation leads to constitutive activation of NF-kB in activated B cell-like (ABC) subtype of DLBCL (95, 97, 100–102). This evidence concerns the gene CD79B and diffuse large B-cell lymphoma.